CD274 and melanoma: Thus far, one CTLA-4 inhibitor and several PD-1/PD-L1 inhibitors (Table 2) have been approved by the FDA for the clinical treatment of melanoma, lung cancer, HNSCC (Table 3), and other solid tumors.